Casey Johnson

A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults.

T. Monath, A. Artenstein, T. Marbury, 2005, Vaccine.

ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) – a second-generation smallpox vaccine for biological defense

T. Monath, R. Weltzin, W. Mundt, 2004, International Journal of Infectious Diseases.

Clonal vaccinia virus grown in cell culture as a new smallpox vaccine

F. Ennis, T. Monath, J. Cruz, 2003, Nature Medicine.

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

R. Walker, R. Coler, S. Reed, 2018, npj Vaccines.

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

R. Walker, R. Coler, S. Reed, 2018, npj Vaccines.

Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.

J. Langley, Ping Li, L. Fries, 2010, The Journal of infectious diseases.

ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) – a second-generation smallpox vaccine for biological defense

T. Monath, R. Weltzin, W. Mundt, 2004, International Journal of Infectious Diseases.